| 曹冉华 苏乌云 邱英 呼群 邢智伟.贝伐珠单抗联合化疗治疗晚期结直肠癌的临床疗效[J].,2015,15(2):277-280 |
| 贝伐珠单抗联合化疗治疗晚期结直肠癌的临床疗效 |
| Efficacy of Bevacizumab Combination with Chemotherapy in the Treatmentof Advanced Colorectal Cancer |
| |
| DOI： |
| 中文关键词: 晚期结直肠癌 化疗 贝伐珠单抗 |
| 英文关键词: Advanced colorectal cancer Chemotherapy Bevacizumab |
| 基金项目: |
|
| 摘要点击次数: 1097 |
| 全文下载次数: 1668 |
| 中文摘要: |
| 目的： 探讨晚期结直肠癌采用 贝伐珠单抗联合化疗 的临床疗效，为临床治疗提供参考。 方法： 按照随机数字表法将 2010 年 2
月 ～ 2013 年 2 月 我院收治的 50 例 晚期结直肠癌患者分为 两组， 观察组采用 贝 伐珠单抗联合奥沙利 铂， 卡培他滨化疗 ， 对照组单
用 奥沙利铂， 卡培他滨进行化疗 ，比较两组的临床疗效、血清肿瘤标志物浓度变化及不良反应。 结果： 化疗 4 个周期后观察组有效
率为 56.00%高于对照组的 24.00%，差异有统计学意义（ P<0.01）， 观察组疾病控制 率为 84.00%高于对照组的 60.00%，差异有统计
学意义（ P<0.05）； 观察组治疗后的 CEA、 CA242、 CA1 9-9 浓度均低于对照组，差异有统计学意义（ P<0.01）； 化疗 后两组不良反应主
要有恶心、呕吐、食欲减低等胃 肠道反应， 乏力 ， 肝功能损害， 骨髓抑制， 脱发， 贫血以及中性粒细胞下降等， 其中观察组乏力 ， 肝功
能损害发生率低于对照组，差异有统计学意义（ P<0.05）， 其余不良反应两组差异无统计学意义（ P>0.05）。 结论： 结直肠癌采用 贝伐
珠单抗联合化疗治疗具有近期疗效好，安全性高等特点，临床有重要参考价值。 |
| 英文摘要: |
| Objective:To explore the clinical efficacy of bevacizumab in combination with chemotherapy in the treatment of
advanced colorectal cancer, and to provide reference for the clinical treatment.Methods:50 cases of patients with advanced colorectal
cancer in our hospital from February 201 0 to February 2013 were divided into two groups according to the random number table method,
the observation group were given bevacizumab combination with Oxaliplatin and Capecitabine, the control group was treated with
Oxaliplatin,Capecitabine chemotherapy, the clinical effect, serum tumor marker concentration changes and adverse reactions of the two
groups were compared.Results:After 4 cycles of chemotherapy, the effective rate of the observation group was 56.00%, higher than that
of the control group (24.00%), and the difference was statistically significant (P<0.01); the disease control rate of the observation group
was 84.00%, higher than that of the control group (60.00%), and the difference was statistically significant (P<0.01); After treatment ,
levels of CEA, CA242,CA19-9 in observation group was lower than those in control group, and the difference was statistically significant
(P<0.01); Adverse reactions after chemotherapy included nausea and vomiting, loss of appetite, fatigue, gastrointestinal reaction, liver
damage, bone marrow suppression, hair loss, anemia and neutropenia; the incidences of fatigue and liver function damage in observation
group were lower than those in control group with statistical differences (P<0.05), other adversereactions in the two groups had no
statistically significant difference (P>0.05).Conclusion:Bevacizumab combined with chemotherapy in treatment of advanced colorectal
cancer has the characteristics of good recent curative effect and high security, and it has very important reference value in clinic. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
